Risk stratification for cardiovascular disease based on prior coronary artery disease, cerebrovascular disease and type 2 diabetes mellitus.
Cardiovascular diseases
Real‐world data
Type 2 diabetes mellitus
Journal
Journal of diabetes investigation
ISSN: 2040-1124
Titre abrégé: J Diabetes Investig
Pays: Japan
ID NLM: 101520702
Informations de publication
Date de publication:
01 Aug 2024
01 Aug 2024
Historique:
revised:
28
06
2024
received:
16
04
2024
accepted:
16
07
2024
medline:
1
8
2024
pubmed:
1
8
2024
entrez:
1
8
2024
Statut:
aheadofprint
Résumé
History of coronary artery disease (CAD), cerebrovascular disease (CeVD), type 2 diabetes and their combined effect on cardiovascular disease are essential for cardiovascular risk management. We investigated the association of prior CAD, prior CeVD, type 2 diabetes and their combination with the risk of cardiovascular disease. This is a historical cohort study including 342,033 participants (aged 18-72 years) followed up for ≥5 years between 2008 and 2016. Participants were classified into eight groups (with or without prior CAD, prior CeVD and type 2 diabetes). Type 2 Diabetes was defined by fasting plasma glucose and glycated hemoglobin levels, and antidiabetic drug prescription. Prior and subsequent CAD and CeVD were identified according to claims using International Classification of Diseases 10th Revision codes, medical procedures and questionnaires. Cox regression models were used to evaluate the risk of cardiovascular events. The median follow-up period was 6.4 years. The incidence of composite cardiovascular events of CAD and CeVD in the CAD-/CeVD-, CAD+/CeVD-, CAD-/CeVD+ and CAD+/CeVD+ groups were 1.92 and 6.94, 25.14 and 31.98 per 1,000 person-years in non-diabetes participants, and 8.66, 18.04, 39.98 and 60.72 in type 2 diabetes patients, respectively. Hazard ratios of cardiovascular events compared with CAD-/CeVD-/non-diabetes were 1.66 (95% confidence interval 1.55-1.78) in CAD-/CeVD-/type 2 diabetes and 1.84 (1.56-2.18) in CAD+/CeVD-/non-diabetes. CeVD+ was linked to a 4-7-fold increase in the risk of cardiovascular events regardless of CAD+ or type 2 diabetes. Type 2 diabetes increased the risk of cardiovascular disease as high as a history of CAD, whereas prior CeVD alone increased the risk of future CeVD without additional effects by type 2 diabetes.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Japan Society for the Promotion of Science (JSPS) KAKENHI
ID : JP 19H04028
Organisme : Taiju Life Social Welfare Foundation
Informations de copyright
© 2024 The Author(s). Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd.
Références
Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2021; 42: 3227–3337.
Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019; 139: e1082–e1143.
Kleindorfer DO, Towfighi A, Chaturvedi S, et al. 2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association/American Stroke Association. Stroke 2021; 52: e364–e467.
Joseph JJ, Deedwania P, Acharya T, et al. Comprehensive management of cardiovascular risk factors for adults with type 2 diabetes: a scientific statement from the American Heart Association. Circulation 2022; 145: e722–e759.
Ormazabal V, Nair S, Elfeky O, et al. Association between insulin resistance and the development of cardiovascular disease. Cardiovasc Diabetol 2018; 17: 122.
Donahoe SM, Stewart GC, McCabe CH, et al. Diabetes and mortality following acute coronary syndromes. JAMA 2007; 298: 765–775.
Arboix A, Rivas A, García‐Eroles L, et al. Cerebral infarction in diabetes: clinical pattern, stroke subtypes, and predictors of in‐hospital mortality. BMC Neurol 2005; 5: 9.
Fujihara K, Yamada‐Harada M, Matsubayashi Y, et al. Accuracy of Japanese claims data in identifying diabetes‐related complications. Pharmacoepidemiol Drug Saf 2021; 30: 594–601.
Steg PG, Bhatt DL, Wilson PW, et al. One‐year cardiovascular event rates in outpatients with atherothrombosis. JAMA 2007; 297: 1197–1206.
Miao B, Hernandez AV, Alberts MJ, et al. Incidence and predictors of major adverse cardiovascular events in patients with established atherosclerotic disease or multiple risk factors. J Am Heart Assoc 2020; 9: e014402.
Goto S, Ikeda Y, Shimada K, et al. One‐year cardiovascular event rates in Japanese outpatients with myocardial infarction, stroke, and atrial fibrillation. Results from the Japan thrombosis registry for atrial fibrillation, coronary, or cerebrovascular events (J‐TRACE). Circ J 2011; 75: 2598–2604.
Oe M, Fujihara K, Harada‐Yamada M, et al. Impact of prior cerebrovascular disease and glucose status on incident cerebrovascular disease in Japanese. Cardiovasc Diabetol 2021; 20: 174.
Lindh M, Banefelt J, Fox KM, et al. Cardiovascular event rates in a high atherosclerotic cardiovascular disease risk population: estimates from Swedish population‐based register data. Eur Heart J Qual Care Clin Outcomes 2019; 5: 225–232.
Lewington S, Whitlock G, Clarke R, et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta‐analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 2007; 370: 1829–1839.
Lewington S, Clarke R, Qizilbash N, et al. Age‐specific relevance of usual blood pressure to vascular mortality: a meta‐analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903–1913.
Kitazawa M, Fujihara K, Osawa T, et al. Risk of coronary artery disease according to glucose abnormality status and prior coronary artery disease in Japanese men. Metabolism 2019; 101: 153991.
Ninomiya T. Japanese legacy cohort studies: the Hisayama study. J Epidemiol 2018; 28: 444–451.
Yamagishi K, Muraki I, Kubota Y, et al. The circulatory risk in communities study (CIRCS): a long‐term epidemiological study for lifestyle‐related disease among Japanese men and women living in communities. J Epidemiol 2019; 29: 83–91.
Sone H, Tanaka S, Tanaka S, et al. Serum level of triglycerides is a potent risk factor comparable to LDL cholesterol for coronary heart disease in Japanese patients with type 2 diabetes: subanalysis of the Japan Diabetes Complications Study (JDCS). J Clin Endocrinol Metab 2011; 96: 3448–3456.
Nørgaard CH, Starkopf L, Gerds TA, et al. Temporal changes in risk of cardiovascular events in people with newly diagnosed type 2 diabetes with and without cardiovascular disease. J Diabetes Complicat 2022; 36: 108126.
Zhao M, Song L, Sun L, et al. Associations of type 2 diabetes onset age with cardiovascular disease and mortality: the Kailuan study. Diabetes Care 2021; 44: 1426–1432.
Cai X, Zhang Y, Li M, et al. Association between prediabetes and risk of all cause mortality and cardiovascular disease: updated meta‐analysis. BMJ 2020; 370: m2297.
Wilcox R, Bousser MG, Betteridge DJ, et al. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial in macroVascular Events 04). Stroke 2007; 38: 865–873.
Mannucci E, Silverii GA. Cardiovascular prevention with glucose‐lowering drugs in type 2 diabetes: an evidence‐based approach to the categories of primary and secondary prevention. Diabetes Obes Metab 2023; 25: 3435–3443.
Davies MJ, Aroda VR, Collins BS, et al. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of diabetes (EASD). Diabetes Care 2022; 45: 2753–2786.
American Diabetes Association Professional Practice Committee. 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes‐2024. Diabetes Care 2024; 47(Suppl 1): S158–S178.
Kabootari M, Hasheminia M, Azizi F, et al. Change in glucose intolerance status and risk of incident cardiovascular disease: Tehran lipid and glucose study. Cardiovasc Diabetol 2020; 19: 41.
Bae YS, Choi S, Lee K, et al. Association of concurrent changes in metabolic health and weight on cardiovascular disease risk: a nationally representative cohort study. J Am Heart Assoc 2019; 8: e011825.